SAN DIEGO, Calif. – October 9, 2006 – Pharmatek Laboratories – a premier pharmaceutical chemistry development organization supporting the pharmaceutical industry – today announced the appointment of Robert Bergstrom, Ph.D. to the new position of vice president, business development. This follows the company’s recent announcement to relocate its San Diego-based operations to a larger facility in December 2006. Dr. Bergstrom has worked as a drug development scientist in contract research organizations and pharmaceutical companies for more than twenty-five years.
“Dr. Bergstrom brings with him a tremendous combination of product development and business development experience, which is necessary for us to continue to expand our pharmaceutical chemistry development business while maintaining our client-centric approach to drug development,” said Timothy Scott, president of Pharmatek. “His comprehensive understanding of analytical chemistry, formulation development and cGMP manufacturing will provide our customers with a complete pharmaceutical chemistry outsourcing resource.”
Bergstrom joins Pharmatek from Cardinal Health, where he served as senior vice president and general manager of its San Diego facility. While at Cardinal, Bergstrom oversaw sterile product development of preclinical and clinical development phases for pharmaceutical and biotechnology companies. Prior to joining Cardinal, Bergstrom worked as a scientist for such companies as Alliance Pharmaceuticals, Gensia, Baxter Healthcare and Merck. Bergstrom received his Ph.D. in physical organic chemistry from the University of California, Santa Cruz and completed his post doctoral research at the University of Toronto.
“Dr. Bergstrom’s extensive experience in drug development will provide our clients with another level of confidence when discussing their development projects,” said Dr. Jeffrey Bibbs, CEO and CSO of Pharmatek. “He is a great addition to what is already an excellent team at Pharmatek, and I know he will contribute significantly to the company’s continued growth and success.”Leave a reply →